Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Azzu, Vian https://orcid.org/0000-0002-0097-7677
Vacca, Michele https://orcid.org/0000-0002-1973-224X
Virtue, Samuel
Allison, Michael
Vidal-Puig, Antonio https://orcid.org/0000-0003-4220-9577
Abstract
Adipose tissue and the liver play significant roles in the regulation of whole-body energy homeostasis, but they have not evolved to cope with the continuous, chronic, nutrient surplus seen in obesity. In this review, we detail how prolonged metabolic stress leads to adipose tissue dysfunction, inflammation, and adipokine release that results in increased lipid flux to the liver. Overall, the upshot of hepatic fat accumulation alongside an insulin-resistant state is that hepatic lipid enzymatic pathways are modulated and overwhelmed, resulting in the selective buildup of toxic lipid species, which worsens the pro-inflammatory and pro-fibrotic shift observed in nonalcoholic steatohepatitis.
Description
Keywords
Adipose Tissue, Fatty Acid Flux, Metabolism, Nonalcoholic Fatty Liver Disease, Adipokines, Adipose Tissue, Adiposity, Animals, Blood Glucose, Energy Metabolism, Humans, Hyperglycemia, Inflammation Mediators, Insulin Resistance, Liver, Non-alcoholic Fatty Liver Disease, Obesity, Prognosis, Risk Factors, Signal Transduction
Journal Title
Gastroenterology
Conference Name
Journal ISSN
0016-5085
1528-0012
1528-0012
Volume Title
158
Publisher
Elsevier BV
Publisher DOI
Sponsorship
British Heart Foundation (RG/18/7/33636)
MRC (Unknown)
Medical Research Council (MC_PC_13030)
European Commission Horizon 2020 (H2020) Societal Challenges (634413)
European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) FP7 Innovative Medicines Initiative (IMI) (777377)
Biotechnology and Biological Sciences Research Council (BB/H002731/1)
Medical Research Council (G0802051)
Medical Research Council (G0400192)
Medical Research Council (MC_UU_12012/2)
Medical Research Council (G0600717)
Medical Research Council (MC_G0802535)
Medical Research Council (MC_UU_12012/5)
MRC (MC_UU_00014/2)
Medical Research Council (MC_PC_12012)
Medical Research Council (G0600717/1)
MRC (Unknown)
Medical Research Council (MC_PC_13030)
European Commission Horizon 2020 (H2020) Societal Challenges (634413)
European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) FP7 Innovative Medicines Initiative (IMI) (777377)
Biotechnology and Biological Sciences Research Council (BB/H002731/1)
Medical Research Council (G0802051)
Medical Research Council (G0400192)
Medical Research Council (MC_UU_12012/2)
Medical Research Council (G0600717)
Medical Research Council (MC_G0802535)
Medical Research Council (MC_UU_12012/5)
MRC (MC_UU_00014/2)
Medical Research Council (MC_PC_12012)
Medical Research Council (G0600717/1)